Business

Manja Bouman has been appointed president and business unit director of DSM Pharmaceutical Products’ Biologics/BioSolutions businesses. Most recently, she was chief executive officer of Regenesance. With operations in Groningen, the Netherlands, and in Brisbane, Australia, DSM’s Biologics business specializes in preclinical through commercial biomanufacturing of recombinant proteins and monoclonal antibodies based on mammalian cell cultures. DSM BioSolutions offers large-scale fermentation for large- and small-molecule active pharmaceutical ingredients for therapeutic proteins and enzymes at DSM’s Capua, Italy, site.

Mark A. De Rosch has been appointed vice president of regulatory drugs and biologics and head of U.S. operations at Voisin Consulting Life Sciences. He brings more than 20 years of experience at pharma and biotech companies, including Vertex Pharmaceuticals. Voisin is a product development consulting firm serving biotech, pharma, and medtech companies.

Paulo Diniz hasbecome interim chief financial officer of Amyris while the company looks to fill the position on a permanent basis. The move follows the resignation of the company’s former CFO, Steve Mills, who will remain with Amyris in an advisory role. Diniz had been president of Amyris Brazil. Based in Emeryville, Calif., Amyris is a renewable chemicals and fuels company.